신경교종 치료 시장 규모 및 예측, 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 범위 : 질환별, 치료 유형별, 등급별, 최종사용자별, 지역별

Glioma Treatment Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease, Treatment Type, Grade, End User, and Geography

US $ 4,450 ￦ 6,105,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 6,450 ￦ 8,850,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,450 ￦ 11,594,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 신경교종 치료 시장은 2022년 41억 3,960만 달러에서 2030년 82억 9,250만 달러에 달할 것으로 예상됩니다. 이 시장은 2022-2030년간 연평균 9.1%의 성장률을 보일 것으로 예상됩니다.

시장 성장은 교모세포종, 퇴행성 성상세포종, 희소교종 등 침습성 뇌종양을 포함한 고악성 신경교종 유병률 증가입니다. 그러나 높은 치료비가 시장 성장을 어느 정도 방해하고 있습니다.

신경교종 치료 시장 시장 기회

브라질, 인도, 중국, 러시아, 남아프리카공화국은 세계에서 가장 빠르게 경제가 성장하고 있는 국가 중 하나입니다. 이들 국가 및 기타 신흥 경제국의 의료 분야는 향후 몇 년동안 빠르게 성장할 것으로 예상됩니다. 이러한 성장의 배경에는 고객 수요의 변화, 의료 서비스에 대한 인식의 변화, 고령화 인구의 지속적인 증가 등이 있습니다. 세계 뇌종양 치료 시장은 의료 분야의 보급과 함께 향후 몇 년동안 크게 성장할 가능성이 높습니다.

신경교종 치료제 시장을 저해하는 요인들

뇌종양 치료에는 많은 비용이 소요되기 때문에 높은 치료비는 환자의 스트레스와 불안의 원인이 되고 있습니다. 치료비 외에도 환자 치료와 관련된 예기치 못한 추가 비용도 부담해야 합니다. 높은 의료비는 치료 계획을 중단하게 만들고, 건강을 위험에 빠뜨리고, 미래에 더 많은 지출을 초래할 수 있습니다. 미국 국립의학도서관에 따르면, 새로 진단된 테모졸로미드(TMZ) 치료로 인한 GBM의 직접 의료비용은 상업적 보험에 가입한 환자에서 상당한 수준이며, 누적 비용은 -268,031달러로 추정됩니다. 악성 뇌종양 환자가 부담하는 의료비용은 같은 인구 통계의 비암 대조군이 부담하는 비용의 20배에 달할 전망입니다.

신경교종 치료제 시장 부문별 개요

신경교종 치료 시장은 유형별로 성상세포종, 희소성 성상세포종, 희소성 교종으로 분류되며, 2022년에는 성상세포종 부문이 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 또한, 이 부문은 2022-2030년간 가장 높은 CAGR을 기록할 것으로 예상됩니다. 이 질환의 유병률 증가와 함께 이 질환과 그 치료에 대한 대중의 인식을 높이기 위한 활동이 활발해지면서 신경교종 치료 시장의 성장을 가속하는 주요 요인 중 하나입니다. 또한, 퇴행성 성상세포종 분야 시장 진출기업들은 연구개발 노력의 확대와 미개척된 신규 시장 부문에서 성장 기회를 얻을 수 있습니다. 치료 방법에 따라 신경교종 치료 시장은 수술, 화학요법, 방사선 요법, 기타로 구분되며, 2022년에는 수술 분야가 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 또한, 수술은 종양을 완전히 제거하기 때문에 가장 선호되는 방법이기 때문에 2022-2030년간 가장 빠른 CAGR로 수요가 증가할 것으로 예상됩니다. 악성도에 따라 신경교종 치료 시장은 저악성 및 고악성으로 구분되며, 2022년에는 고악성 부문이 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다. 또한 이 부문은 2022-2030년간 가장 빠른 CAGR로 수요가 증가할 것으로 예상됩니다. 보다 효과적인 치료법과 치료법을 개발하기 위해 고악성 종양을 더 깊이 이해하기 위한 여러 연구가 진행 중입니다. 신경교종 치료 시장은 최종 사용자에 따라 병원 및 클리닉과 외래 진료소로 구분되며, 2022년에는 병원 및 클리닉 부문이 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 또한, 이 부문은 2022-2030년간 가장 빠른 CAGR로 수요가 증가할 것으로 예상됩니다. 또한, 병원 수 증가, 고급 진단 플랫폼의 채택, 신흥 시장에서의 병원 접근성 향상은 예측 기간 동안 병원 부문의 신경교종 치료 시장 성장에 유리한 기회를 제공할 것입니다.

신경교종 치료제 시장 지리적 개요

북미가 세계 신경교종 치료 시장에서 가장 큰 점유율을 차지하고 있으며, 아시아태평양은 세계 신경교종 치료 시장에서 가장 빠르게 성장하는 지역입니다. 북미 시장은 주로 뇌종양 유병률 증가, 신경교종 치료의 기술 발전, 흡연자 증가로 인해 예측 기간 동안 성장할 것으로 예상됩니다. 아시아태평양은 세계 신경교종 치료 검사 시장에서 가장 높은 CAGR을 기록했습니다. 이 지역 시장은 중국, 인도, 일본을 포함한 국가에서 향후 몇 년동안 크게 성장할 것으로 예상됩니다. 아시아태평양 시장은 뇌종양 치료에 대한 수요 증가와 뇌종양 유병률 증가로 인해 성장할 것으로 예상됩니다. 따라서 이 지역은 예측 기간 동안 신경교종 치료 시장의 기업들에게 큰 성장 잠재력을 가지고 있습니다.

신경교종 치료제 시장에 대한 보고서를 작성할 때 참고한 1차 및 2차 정보는 세계은행 데이터, NHS(National Health Service), FDA(Food and Drug Administration), EMA(European Medicines Agency), EPA(Environmental Protection Agency) 등이 있습니다.

목차

제1장 서론

제2장 주요 요약

• 주요 인사이트

제3장 조사 방법

• 조사 범위
• 2차 조사
• 1차 조사

제4장 신경교종 치료 시장 상황

• PEST 분석
  • 세계의 PEST 분석

제5장 신경교종 치료 시장 - 주요 산업 역학

• 시장 성장 촉진요인
• 주요 시장 성장 억제요인
• 주요 시장 기회
• 향후 동향
• 영향 분석

제6장 신경교종 치료 시장 : 세계 시장 분석

• 신경교종 치료 시장 매출, 2022년-2030년

제7장 신경교종 치료 시장 신경교종치료 세계 시장 - 2030년까지 매출과 예측 : 질환별

• 신경교종 치료 시장 매출 점유율, 질환별, 2022년·2030년(%)
• Astrocytoma
• Oligoastrocytoma
• Oligodendroglioma

제8장 신경교종치료 세계 시장 : 2030년까지 매출과 예측 : 치료 유형별

• 신경교종 치료 시장 2022년 및 2030년 치료 유형별 판매량 점유율(%)
• 수술 요법
• 화학 요법
• 방사선 요법
• 기타

제9장 신경교종치료 세계 시장 : 2030년까지 매출과 예측 : 등급별

• 신경교종 치료 시장 2022년 및 2030년 등급별 매출 점유율(%)
• 저악성도
• 고악성도

제10장 신경교종치료 세계 시장 - 최종사용자별 매출과 2030년까지 예측

• 신경교종 치료 시장 최종사용자별 매출 점유율(2022년 및 2030년)
• 병원 및 진료소
• 외래수술센터(ASC)

제11장 신경교종 치료 시장 - 지역별 분석

• 북미
  • 멕시코
• 유럽
  • 기타 유럽
• 아시아태평양
  • 기타 아시아태평양
• 중동 및 아프리카
  • 기타 중동 및 아프리카
• 중남미
  • 기타 중남미

제12장 COVID-19 전후의 영향

• COVID-19 전후의 영향

제13장 신경교종 치료 시장 업계 상황

• 시장 기업의 성장 전략(%)
• 유기적 전개
• 무기적 전개

제14장 기업 개요

• F. Hoffmann-La Roche Ltd
• Arbor Pharmaceuticals LLC
• Merck & Co Inc
• Sun Pharmaceutical Industries Ltd
• Amgen Inc
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc
• Amneal Pharmaceuticals Inc
• Karyopharm Therapeutics Inc
• Biocon Ltd

제15장 부록

LSH

영문 목차

영문목차

The global glioma treatment market is expected to reach US$ 8,292.5 million in 2030 from US$ 4,139.6 million in 2022. The market is projected to grow with a CAGR of 9.1% from 2022 to 2030.

The market's growth is the increasing prevalence of high-grade gliomas, including aggressive brain tumors such as glioblastomas, anaplastic astrocytomas, and oligodendrogliomas. However, high treatment costs hamper the market's growth to a certain extent.

Market Opportunities of Glioma Treatment Market

Brazil, India, China, Russia, and South Africa are among the fastest-growing economies in the world. The healthcare sectors in these countries and other developing economies are projected to expand rapidly in the coming years. The expected growth is due to changes in customer demand, increased awareness about healthcare services, and a continuous rise in the aging population. The global brain cancer treatment market is likely to grow significantly in the coming years with the proliferation of the healthcare sector.

Factors Hampering Glioma Treatment Market

Treating brain tumors can be expensive, and the high cost of treatments becomes a cause of stress and anxiety for patients. In addition to the treatment cost, people need to bear additional unplanned costs related to patient care. High medical costs compel people to discontinue their treatment plans, which may put their health at risk and lead to further costs in the future. According to the National Library of Medicine, the direct medical costs of newly diagnosed, Temozolomide-treated (TMZ) GBM are substantial in commercially insured patients, with estimated total cumulative costs of ~US$ 268,031. The healthcare costs incurred by patients with malignant brain tumors are 20 times higher than those borne by non-cancer control groups with the same demographics.

Glioma Treatment Market: Segmental Overview

The glioma treatment market is segmented based on type into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest market share in 2022. Furthermore, the segment is expected to register the highest CAGR from 2022 to 2030. An upsurge in activities to raise public awareness of this condition and its treatment, coupled with the increasing prevalence of this disease, are among the major factors fueling the glioma treatment market growth. In addition, companies in the market for the anaplastic astrocytoma segment may derive growth opportunities from growing R&D efforts and new, untapped market segments. Based on treatment, the glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. In 2022, the surgery segment held the market's largest share. Also, the same segment is expected to growing demand at the fastest CAGR from 2022 to 2030, owing to the surgery being the most preferred technique as it removes the tumor completely. Based on grade, the glioma treatment market is segmented into Low Grade and High Grade. In 2022, the high-grade segment held the market's largest share. Also, the same segment is expected to growing demand at the fastest CAGR from 2022 to 2030. Multiple research studies are underway to understand better high-grade tumors to develop more effective treatments or therapies. The glioma treatment market is segmented based on end-users into hospitals & clinics, and ambulatory care centres. In 2022, the hospital & clinics segment held the largest market share. Furthermore, the same segment is expected to anticipate growth in demand at the fastest CAGR from 2022 to 2030. Further, the increasing number of hospitals, adoption of advanced diagnostic platforms, and growing accessibility of hospitals in developing nations would offer lucrative opportunities for the growth of the glioma treatment market for the hospital segment during the forecast period.

Glioma Treatment Market: Geographical Overview

North America holds the largest share of the global glioma treatment market, whereas the Asia Pacific is the fastest-growing region in the global glioma treatment market. The market in North America is expected to grow during the forecast period, primarily driven by the increasing prevalence of brain tumors, technological advancements in glioma treatment, and the rising number of smokers. Asia Pacific registered the highest CAGR in the global glioma treatment testing market. The market in the region is expected to grow significantly in countries including China, India, and Japan in the coming years. The Asia Pacific market is expected to grow due to the increasing demand for brain cancer treatments and the rising prevalence of brain tumors. Therefore, the region holds huge potential for the glioma treatment market players to grow during the forecast period.

A few of the primary and secondary sources referred to while preparing the report on the glioma treatment market are the World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and EPA (Environmental Protection Agency).

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the glioma treatment.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the global glioma treatment, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global glioma treatment trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Glioma Treatment Market Landscape

• 4.1 Overview
• 4.2 PEST Analysis
  • 4.2.1 Global PEST Analysis

5. Glioma Treatment Market - Key Industry Dynamics

• 5.1 Market Drivers
  • 5.1.1 Initiatives by Regional and State Governments to Provide Patients Access to Treatment
  • 5.1.2 Increase in Prevalence of High-Grade Glioma
• 5.2 Key Market Restraints
  • 5.2.1 High Cost of Diagnosis
• 5.3 Key Market Opportunities
  • 5.3.1 Advancements in Healthcare Sector in Emerging Economies
• 5.4 Future Trends
  • 5.4.1 Surge in Drug Approvals for Glioma Treatment
• 5.5 Impact Analysis:

6. Glioma Treatment Market - Global Market Analysis

• 6.1 Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030

7. Global Glioma Treatment Market - Revenue and Forecast to 2030 - by Disease

• 7.1 Overview
• 7.2 Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
• 7.3 Astrocytoma
  • 7.3.1 Overview
  • 7.3.2 Astrocytoma: Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 Oligoastrocytoma
  • 7.4.1 Overview
  • 7.4.2 Oligoastrocytoma: Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
• 7.5 Oligodendroglioma
  • 7.5.1 Overview
  • 7.5.2 Oligodendroglioma: Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. Global Glioma Treatment Market - Revenue and Forecast to 2030 - by Treatment Type

• 8.1 Overview
• 8.2 Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
• 8.3 Surgery
  • 8.3.1 Overview
  • 8.3.2 Surgery: Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
• 8.4 Chemotherapy
  • 8.4.1 Overview
  • 8.4.2 Chemotherapy: Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
• 8.5 Radiation Therapy
  • 8.5.1 Overview
  • 8.5.2 Radiation Therapy: Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
• 8.6 Others
  • 8.6.1 Overview
  • 8.6.2 Others: Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. Global Glioma Treatment Market - Revenue and Forecast to 2030 - by Grade

• 9.1 Overview
• 9.2 Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
• 9.3 Low Grade
  • 9.3.1 Overview
  • 9.3.2 Low Grade: Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
    • 9.3.2.1 Grade I: Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
    • 9.3.2.2 Grade II: Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
• 9.4 High Grade
  • 9.4.1 Overview
  • 9.4.2 High Grade: Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
    • 9.4.2.1 Grade III: Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
    • 9.4.2.2 Grade IV: Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

10. Global Glioma Treatment Market - Revenue and Forecast to 2030 - by End User

• 10.1 Overview
• 10.2 Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
• 10.3 Hospital & Clinics
  • 10.3.1 Overview
  • 10.3.2 Hospital & Clinics: Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
• 10.4 Ambulatory Surgical Centers
  • 10.4.1 Overview
  • 10.4.2 Ambulatory Surgical Centers: Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

11. Glioma Treatment Market - Geographical Analysis

• 11.1 North America Glioma Treatment Market, Revenue and Forecast To 2030
  • 11.1.1 Overview
  • 11.1.2 North America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • 11.1.3 North America Glioma Treatment Market, by Disease
  • 11.1.4 North America Glioma Treatment Market, by Treatment Type
  • 11.1.5 North America Glioma Treatment Market, by Grade
    • 11.1.5.1 North America Glioma Treatment Market, by Low Grade
    • 11.1.5.2 North America Glioma Treatment Market, by High Grade
  • 11.1.6 North America Glioma Treatment Market, by End User
  • 11.1.7 North America Glioma Treatment Market, by Country
    • 11.1.7.1 US
      • 11.1.7.1.1 US Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.1.7.1.2 US Glioma Treatment Market, by Disease
      • 11.1.7.1.3 US Glioma Treatment Market, by Treatment Type
      • 11.1.7.1.4 US Glioma Treatment Market, by Grade
      • 11.1.7.1.4.1 US Glioma Treatment Market, by Low Grade
      • 11.1.7.1.4.2 US Glioma Treatment Market, by High Grade
      • 11.1.7.1.5 US Glioma Treatment Market, by End User
    • 11.1.7.2 Canada
      • 11.1.7.2.1 Canada Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.1.7.2.2 Canada Glioma Treatment Market, by Disease
      • 11.1.7.2.3 Canada Glioma Treatment Market, by Treatment Type
      • 11.1.7.2.4 Canada Glioma Treatment Market, by Grade
      • 11.1.7.2.4.1 Canada Glioma Treatment Market, by Low Grade
      • 11.1.7.2.4.2 Canada Glioma Treatment Market, by High Grade
      • 11.1.7.2.5 Canada Glioma Treatment Market, by End User
    • 11.1.7.3 Mexico
      • 11.1.7.3.1 Mexico Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.1.7.3.2 Mexico Glioma Treatment Market, by Disease
      • 11.1.7.3.3 Mexico Glioma Treatment Market, by Treatment Type
      • 11.1.7.3.4 Mexico Glioma Treatment Market, by Grade
      • 11.1.7.3.4.1 Mexico Glioma Treatment Market, by Low Grade
      • 11.1.7.3.4.2 Mexico Glioma Treatment Market, by High Grade
      • 11.1.7.3.5 Mexico Glioma Treatment Market, by End User
• 11.2 Europe Glioma Treatment Market, Revenue and Forecast to 2030
  • 11.2.1 Overview
  • 11.2.2 Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • 11.2.3 Europe Glioma Treatment Market, by Disease
  • 11.2.4 Europe Glioma Treatment Market, by Treatment Type
  • 11.2.5 Europe Glioma Treatment Market, by Grade
    • 11.2.5.1 Europe Glioma Treatment Market, by Low Grade
    • 11.2.5.2 Europe Glioma Treatment Market, by High Grade
  • 11.2.6 Europe Glioma Treatment Market, by End User
  • 11.2.7 Europe Glioma Treatment Market, by Country
    • 11.2.7.1 UK
      • 11.2.7.1.1 UK Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.2.7.1.2 UK Glioma Treatment Market, by Disease
      • 11.2.7.1.3 UK Glioma Treatment Market, by Treatment Type
      • 11.2.7.1.4 UK Glioma Treatment Market, by Grade
      • 11.2.7.1.4.1 UK Glioma Treatment Market, by Low Grade
      • 11.2.7.1.4.2 UK Glioma Treatment Market, by High Grade
      • 11.2.7.1.5 UK Glioma Treatment Market, by End User
    • 11.2.7.2 Germany
      • 11.2.7.2.1 Germany Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.2.7.2.2 Germany Glioma Treatment Market, by Disease
      • 11.2.7.2.3 Germany Glioma Treatment Market, by Treatment Type
      • 11.2.7.2.4 Germany Glioma Treatment Market, by Grade
      • 11.2.7.2.4.1 Germany Glioma Treatment Market, by Low Grade
      • 11.2.7.2.4.2 Germany Glioma Treatment Market, by High Grade
      • 11.2.7.2.5 Germany Glioma Treatment Market, by End User
    • 11.2.7.3 France
      • 11.2.7.3.1 France Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.2.7.3.2 France Glioma Treatment Market, by Disease
      • 11.2.7.3.3 France Glioma Treatment Market, by Treatment Type
      • 11.2.7.3.4 France Glioma Treatment Market, by Grade
      • 11.2.7.3.4.1 France Glioma Treatment Market, by Low Grade
      • 11.2.7.3.4.2 France Glioma Treatment Market, by High Grade
      • 11.2.7.3.5 France Glioma Treatment Market, by End User
    • 11.2.7.4 Italy
      • 11.2.7.4.1 Italy Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.2.7.4.2 Italy Glioma Treatment Market, by Disease
      • 11.2.7.4.3 Italy Glioma Treatment Market, by Treatment Type
      • 11.2.7.4.4 Italy Glioma Treatment Market, by Grade
      • 11.2.7.4.4.1 Italy Glioma Treatment Market, by Low Grade
      • 11.2.7.4.4.2 Italy Glioma Treatment Market, by High Grade
      • 11.2.7.4.5 Italy Glioma Treatment Market, by End User
    • 11.2.7.5 Spain
      • 11.2.7.5.1 Spain Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.2.7.5.2 Spain Glioma Treatment Market, by Disease
      • 11.2.7.5.3 Spain Glioma Treatment Market, by Treatment Type
      • 11.2.7.5.4 Spain Glioma Treatment Market, by Grade
      • 11.2.7.5.4.1 Spain Glioma Treatment Market, by Low Grade
      • 11.2.7.5.4.2 Spain Glioma Treatment Market, by High Grade
      • 11.2.7.5.5 Spain Glioma Treatment Market, by End User
    • 11.2.7.6 Rest of Europe
      • 11.2.7.6.1 Rest of Europe Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.2.7.6.2 Rest of Europe Glioma Treatment Market, by Disease
      • 11.2.7.6.3 Rest of Europe Glioma Treatment Market, by Treatment Type
      • 11.2.7.6.4 Rest of Europe Glioma Treatment Market, by Grade
      • 11.2.7.6.4.1 Rest of Europe Glioma Treatment Market, by Low Grade
      • 11.2.7.6.4.2 Rest of Europe Glioma Treatment Market, by High Grade
      • 11.2.7.6.5 Rest of Europe Glioma Treatment Market, by End User
• 11.3 Asia Pacific Glioma Treatment Market, Revenue and Forecast to 2030
  • 11.3.1 Overview
  • 11.3.2 Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • 11.3.3 Asia Pacific Glioma Treatment Market, by Disease
  • 11.3.4 Asia Pacific Glioma Treatment Market, by Treatment Type
  • 11.3.5 Asia Pacific Glioma Treatment Market, by Grade
    • 11.3.5.1 Asia Pacific Glioma Treatment Market, by Low Grade
    • 11.3.5.2 Asia Pacific Glioma Treatment Market, by High Grade
  • 11.3.6 Asia Pacific Glioma Treatment Market, by End User
  • 11.3.7 Asia Pacific Glioma Treatment Market, by Country
    • 11.3.7.1 China
      • 11.3.7.1.1 China Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.3.7.1.2 China Glioma Treatment Market, by Disease
      • 11.3.7.1.3 China Glioma Treatment Market, by Treatment Type
      • 11.3.7.1.4 China Glioma Treatment Market, by Grade
      • 11.3.7.1.4.1 China Glioma Treatment Market, by Low Grade
      • 11.3.7.1.4.2 China Glioma Treatment Market, by High Grade
      • 11.3.7.1.5 China Glioma Treatment Market, by End User
    • 11.3.7.2 Japan
      • 11.3.7.2.1 Japan Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.3.7.2.2 Japan Glioma Treatment Market, by Disease
      • 11.3.7.2.3 Japan Glioma Treatment Market, by Treatment Type
      • 11.3.7.2.4 Japan Glioma Treatment Market, by Grade
      • 11.3.7.2.4.1 Japan Glioma Treatment Market, by Low Grade
      • 11.3.7.2.4.2 Japan Glioma Treatment Market, by High Grade
      • 11.3.7.2.5 Japan Glioma Treatment Market, by End User
    • 11.3.7.3 India
      • 11.3.7.3.1 India Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.3.7.3.2 India Glioma Treatment Market, by Disease
      • 11.3.7.3.3 India Glioma Treatment Market, by Treatment Type
      • 11.3.7.3.4 India Glioma Treatment Market, by Grade
      • 11.3.7.3.4.1 India Glioma Treatment Market, by Low Grade
      • 11.3.7.3.4.2 India Glioma Treatment Market, by High Grade
      • 11.3.7.3.5 India Glioma Treatment Market, by End User
    • 11.3.7.4 South Korea
      • 11.3.7.4.1 South Korea Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.3.7.4.2 South Korea Glioma Treatment Market, by Disease
      • 11.3.7.4.3 South Korea Glioma Treatment Market, by Treatment Type
      • 11.3.7.4.4 South Korea Glioma Treatment Market, by Grade
      • 11.3.7.4.4.1 South Korea Glioma Treatment Market, by Low Grade
      • 11.3.7.4.4.2 South Korea Glioma Treatment Market, by High Grade
      • 11.3.7.4.5 South Korea Glioma Treatment Market, by End User
    • 11.3.7.5 Australia
      • 11.3.7.5.1 Australia Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.3.7.5.2 Australia Glioma Treatment Market, by Disease
      • 11.3.7.5.3 Australia Glioma Treatment Market, by Treatment Type
      • 11.3.7.5.4 Australia Glioma Treatment Market, by Grade
      • 11.3.7.5.4.1 Australia Glioma Treatment Market, by Low Grade
      • 11.3.7.5.4.2 Australia Glioma Treatment Market, by High Grade
      • 11.3.7.5.5 Australia Glioma Treatment Market, by End User
    • 11.3.7.6 Rest of Asia Pacific
      • 11.3.7.6.1 Rest of Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.3.7.6.2 Rest of Asia Pacific Glioma Treatment Market, by Disease
      • 11.3.7.6.3 Rest of Asia Pacific Glioma Treatment Market, by Treatment Type
      • 11.3.7.6.4 Rest of Asia Pacific Glioma Treatment Market, by Grade
      • 11.3.7.6.4.1 Rest of Asia Pacific Glioma Treatment Market, by Low Grade
      • 11.3.7.6.4.2 Rest of Asia Pacific Glioma Treatment Market, by High Grade
      • 11.3.7.6.5 Rest of Asia Pacific Glioma Treatment Market, by End User
• 11.4 Middle East & Africa Glioma Treatment Market, Revenue and Forecast to 2030
  • 11.4.1 Overview
  • 11.4.2 Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • 11.4.3 Middle East & Africa Glioma Treatment Market, by Disease
  • 11.4.4 Middle East & Africa Glioma Treatment Market, by Treatment Type
  • 11.4.5 Middle East & Africa Glioma Treatment Market, by Grade
    • 11.4.5.1 Middle East & Africa Glioma Treatment Market, by Low Grade
    • 11.4.5.2 Middle East & Africa Glioma Treatment Market, by High Grade
  • 11.4.6 Middle East & Africa Glioma Treatment Market, by End User
  • 11.4.7 Middle East & Africa Glioma Treatment Market, by Country
    • 11.4.7.1 Saudi Arabia
      • 11.4.7.1.1 Saudi Arabia Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.4.7.1.2 Saudi Arabia Glioma Treatment Market, by Disease
      • 11.4.7.1.3 Saudi Arabia Glioma Treatment Market, by Treatment Type
      • 11.4.7.1.4 Saudi Arabia Glioma Treatment Market, by Grade
      • 11.4.7.1.4.1 Saudi Arabia Glioma Treatment Market, by Low Grade
      • 11.4.7.1.4.2 Saudi Arabia Glioma Treatment Market, by High Grade
      • 11.4.7.1.5 Saudi Arabia Glioma Treatment Market, by End User
    • 11.4.7.2 South Africa
      • 11.4.7.2.1 South Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.4.7.2.2 South Africa Glioma Treatment Market, by Disease
      • 11.4.7.2.3 South Africa Glioma Treatment Market, by Treatment Type
      • 11.4.7.2.4 South Africa Glioma Treatment Market, by Grade
      • 11.4.7.2.4.1 South Africa Glioma Treatment Market, by Low Grade
      • 11.4.7.2.4.2 South Africa Glioma Treatment Market, by High Grade
      • 11.4.7.2.5 South Africa Glioma Treatment Market, by End User
    • 11.4.7.3 UAE
      • 11.4.7.3.1 UAE Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.4.7.3.2 UAE Glioma Treatment Market, by Disease
      • 11.4.7.3.3 UAE Glioma Treatment Market, by Treatment Type
      • 11.4.7.3.4 UAE Glioma Treatment Market, by Grade
      • 11.4.7.3.4.1 UAE Glioma Treatment Market, by Low Grade
      • 11.4.7.3.4.2 UAE Glioma Treatment Market, by High Grade
      • 11.4.7.3.5 UAE Glioma Treatment Market, by End User
    • 11.4.7.4 Rest of Middle East & Africa
      • 11.4.7.4.1 Rest of Middle East & Africa Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.4.7.4.2 Rest of Middle East & Africa Glioma Treatment Market, by Disease
      • 11.4.7.4.3 Rest of Middle East & Africa Glioma Treatment Market, by Treatment Type
      • 11.4.7.4.4 Rest of Middle East & Africa Glioma Treatment Market, by Grade
      • 11.4.7.4.4.1 Rest of Middle East & Africa Glioma Treatment Market, by Low Grade
      • 11.4.7.4.4.2 Rest of Middle East & Africa Glioma Treatment Market, by High Grade
      • 11.4.7.4.5 Rest of Middle East & Africa Glioma Treatment Market, by End User
• 11.5 South & Central America Glioma Treatment Market, Revenue and Forecast to 2030
  • 11.5.1 Overview
  • 11.5.2 South & Central America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
  • 11.5.3 South & Central America Glioma Treatment Market, by Disease
  • 11.5.4 South & Central America Glioma Treatment Market, by Treatment Type
  • 11.5.5 South & Central America Glioma Treatment Market, by Grade
    • 11.5.5.1 South & Central America Glioma Treatment Market, by Low Grade
    • 11.5.5.2 South & Central America Glioma Treatment Market, by High Grade
  • 11.5.6 South & Central America Glioma Treatment Market, by End User
    • 11.5.6.1 South & Central America Glioma Treatment Market, by Country
    • 11.5.6.2 Brazil
      • 11.5.6.2.1 Brazil Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.5.6.2.2 Brazil Glioma Treatment Market, by Disease
      • 11.5.6.2.3 Brazil Glioma Treatment Market, by Treatment Type
      • 11.5.6.2.4 Brazil Glioma Treatment Market, by Grade
      • 11.5.6.2.4.1 Brazil Glioma Treatment Market, by Low Grade
      • 11.5.6.2.4.2 Brazil Glioma Treatment Market, by High Grade
      • 11.5.6.2.5 Brazil Glioma Treatment Market, by End User
    • 11.5.6.3 Argentina
      • 11.5.6.3.1 Argentina Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.5.6.3.2 Argentina Glioma Treatment Market, by Disease
      • 11.5.6.3.3 Argentina Glioma Treatment Market, by Treatment Type
      • 11.5.6.3.4 Argentina Glioma Treatment Market, by Grade
      • 11.5.6.3.4.1 Argentina Glioma Treatment Market, by Low Grade
      • 11.5.6.3.4.2 Argentina Glioma Treatment Market, by High Grade
      • 11.5.6.3.5 Argentina Glioma Treatment Market, by End User
    • 11.5.6.4 Rest of South & Central America
      • 11.5.6.4.1 Rest of South & Central America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.5.6.4.2 Rest of South & Central America Glioma Treatment Market, by Disease
      • 11.5.6.4.3 Rest of South & Central America Glioma Treatment Market, by Treatment Type
      • 11.5.6.4.4 Rest of South & Central America Glioma Treatment Market, by Grade
      • 11.5.6.4.4.1 Rest of South & Central America Glioma Treatment Market, by Low Grade
      • 11.5.6.4.4.2 Rest of South & Central America Glioma Treatment Market, by High Grade
      • 11.5.6.4.5 Rest of South & Central America Glioma Treatment Market, by End User

12. Pre & Post Covid-19 Impact

• 12.1 Pre & Post Covid-19 Impact

13. Glioma Treatment Market Industry Landscape

• 13.1 Overview
• 13.2 Growth Strategies Done by the Companies in the Market, (%)
• 13.3 Organic Developments
  • 13.3.1 Overview
• 13.4 Inorganic Developments
  • 13.4.1 Overview

14. Company Profiles

• 14.1 F. Hoffmann-La Roche Ltd
  • 14.1.1 Key Facts
  • 14.1.2 Business Description
  • 14.1.3 Products and Services
  • 14.1.4 Financial Overview
  • 14.1.5 SWOT Analysis
  • 14.1.6 Key Developments
• 14.2 Arbor Pharmaceuticals LLC
  • 14.2.1 Key Facts
  • 14.2.2 Business Description
  • 14.2.3 Products and Services
  • 14.2.4 Financial Overview
  • 14.2.5 SWOT Analysis
  • 14.2.6 Key Developments
• 14.3 Merck & Co Inc
  • 14.3.1 Key Facts
  • 14.3.2 Business Description
  • 14.3.3 Products and Services
  • 14.3.4 Financial Overview
  • 14.3.5 SWOT Analysis
  • 14.3.6 Key Developments
• 14.4 Sun Pharmaceutical Industries Ltd
  • 14.4.1 Key Facts
  • 14.4.2 Business Description
  • 14.4.3 Products and Services
  • 14.4.4 Financial Overview
  • 14.4.5 SWOT Analysis
  • 14.4.6 Key Developments
• 14.5 Amgen Inc
  • 14.5.1 Key Facts
  • 14.5.2 Business Description
  • 14.5.3 Products and Services
  • 14.5.4 Financial Overview
  • 14.5.5 SWOT Analysis
  • 14.5.6 Key Developments
• 14.6 Teva Pharmaceutical Industries Ltd
  • 14.6.1 Key Facts
  • 14.6.2 Business Description
  • 14.6.3 Products and Services
  • 14.6.4 Financial Overview
  • 14.6.5 SWOT Analysis
  • 14.6.6 Key Developments
• 14.7 Pfizer Inc
  • 14.7.1 Key Facts
  • 14.7.2 Business Description
  • 14.7.3 Products and Services
  • 14.7.4 Financial Overview
  • 14.7.5 SWOT Analysis
  • 14.7.6 Key Developments
• 14.8 Amneal Pharmaceuticals Inc
  • 14.8.1 Key Facts
  • 14.8.2 Business Description
  • 14.8.3 Products and Services
  • 14.8.4 Financial Overview
  • 14.8.5 SWOT Analysis
  • 14.8.6 Key Developments
• 14.9 Karyopharm Therapeutics Inc
  • 14.9.1 Key Facts
  • 14.9.2 Business Description
  • 14.9.3 Products and Services
  • 14.9.4 Financial Overview
  • 14.9.5 SWOT Analysis
  • 14.9.6 Key Developments
• 14.10 Biocon Ltd
  • 14.10.1 Key Facts
  • 14.10.2 Business Description
  • 14.10.3 Products and Services
  • 14.10.4 Financial Overview
  • 14.10.5 SWOT Analysis
  • 14.10.6 Key Developments

15. Appendix

• 15.1 About Us
• 15.2 Glossary of Terms

관련자료